PTPA and chronic myelogenous leukemia, BCR-ABL1 positive: Likewise, PP2A activity was inhibited in a variety of cancers including chronic myeloid leukemia (CML), acute myeloid leukemia (AML), polycythemia vera (PV), and lung cancer (9–12).